Arie Belldegrun - Jan 12, 2022 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
Director
Signature
/s/ Veer Bhavnagri, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Jan 12, 2022
Transactions value $
$1,953,491
Form type
4
Date filed
1/14/2022, 11:02 AM
Previous filing
Mar 28, 2022
Next filing
Apr 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Purchase $1.95M +155K +387.6% $12.60 195K Jan 12, 2022 See footnote F1, F2
holding ALLO Common Stock 372K Jan 12, 2022 Direct
holding ALLO Common Stock 1.8M Jan 12, 2022 See footnote F3
holding ALLO Common Stock 4.71M Jan 12, 2022 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were purchased by Bellco Legacy LLC at an average price of $12.60 per unit, calculated from the price range of $12.35 to $13.00.
F2 The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
F3 The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 The securities are held in the name of Bellco Legacy IV LLC, of which the reporting person and Rebecka Belldegrun are the managers.